Factors associated with outcomes in organophosphate and carbamate poisoning: a retrospective study
- 4 Downloads
Organophosphate and carbamate (OPC) poisoning is a major global health hazard requiring immediate medical intervention. Atropine (ATR) is an essential antidote in organophosphate and carbamate poisoning, with the inclusion of cholinesterase reactivators and other anticholinergics, namely pralidoxime (PAM) and glycopyrrolate (GPR). This study aimed to compare the efficacy of various treatment regimens and identify the factors affecting mortality. The data of patients presented at the emergency unit with the consumption of OPC compounds between the years 2013 and 2017 were retrospectively reviewed. The study population was then categorized into four treatment patterns (1) ATR alone, (2) ATR and PAM, (3) ATR and GPR, (4) ATR, PAM and GPR. The outcome of the patients was assessed in terms of survival, intubation, ICU days, and days of ventilation and hospitalization. Univariate and multivariate analyses were performed to investigate the risk factors associated with mortality and odds ratio (OR). A total of 441 patients were included in the study, of which 69.16% were males, and 375 patients survived. Consumption of poison with a suicidal intention was reported in 98.19% of the patients, and the treatment with ATR and PAM (42.86%) was observed to have lower days of ventilation in comparison to the treatment with ATR and GPR (p = 0.003). Patients requiring intubation were also lowest in the group treated with ATR and PAM (27.51%). The age group of > 50 years (OR 4.275 [CI 2.179–8.387]), male gender (OR 2.608 [CI 1.258–5.406]), and the treatment pattern with ATR, PAM and GPR (OR 2.233 [CI 1.002–4.040]) were independently associated with mortality. In summary, male gender, elderly population, and treatment patterns followed adversely affected the outcome in patients with OPC poisoning.
KeywordsAtropine Carbamate Glycopyrrolate Organophosphate Older age Pralidoxime
We would like to thank Manipal Academy of Higher Education, Department of Medicine, Kasturba Medical College, Department of Pharmacy practice, Manipal College of Pharmaceutical Sciences, Centre for Toxicovigilance and Drug Safety, and the staff for supporting us during the study. We specially thank Ms.Pooja Poojari for helping us with the submission process.
The authors declare that they have no funding.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
- 1.Palaniappen V (2013) Current concepts in the management of organophosphorus compound poisoning Medicine update. The Association of Physician of India, Mumbai, pp 427–433Google Scholar
- 8.Kumaraswamy RC, Madhavi KMS, Basavanthappa SP, Gowda MRN (2014) Open-label randomized controlled study comparing continuous infusion versus intermittent bolus dose of atropine with or without pralidoxime in the treatment of organophosphorus poisoning in a teaching hospital. SMJ 17:3–6Google Scholar
- 12.Bardin PG, Van Eeden SF, Joubert JR (1987) Intensive care management of acute organophosphate poisoning. A 7-year experience in the Western Cape. South Afr Med J 72:593–597Google Scholar
- 15.Poisoning Severity Score (PSS) IPCS/EAPCCT. https://www.who.int/ipcs/poisons/pss.pdf/. Accessed 30 Mar 2019
- 17.Kumar Mr, Vignan Kumar G, Kumar Ss, Subrahmanyam B, Veeraprasad M, Rammohan P, Srinivas M, Babu Pr, Agrawal A (2014) A retrospective analysis of acute organophosphorus poisoning cases admitted to the tertiary care teaching hospital in South India. Ann Afr Med 13:71PubMedCrossRefPubMedCentralGoogle Scholar
- 19.Somasundaram KV, Patil A, Shukla S (2009) Epidemiological Profile of OP poisoning cases Treated at Pravara Hospital, Loni, India. Indian J Prev Soc Med 40:184–188Google Scholar
- 27.Almutairi MK, Almoaiqel FA, Alanazi A, Aljerian N, Alqahtani A, Harthy N Al, Qureshi S, Kumar S (2016) A report on the incidence of organophosphate poisoning among patients admitted to King Abdul-Aziz Medical City, Riyadh, Saudi Arabia over a Period of 12 years. Br J Med Med Res 13:1–8CrossRefGoogle Scholar
- 30.Syed S, Gurcoo SA, Farooqui AK, Nisa W, Sofi K (2015) Is the World Health Organization-recommended dose of pralidoxime effective in the treatment of organophosphorus poisoning? A randomized, double-blinded and placebo-controlled trial. Saudi J Anaesth 9:49–54PubMedPubMedCentralCrossRefGoogle Scholar
- 35.Mahesh M, Gowdar M, Venkatesh CR (2013) A study on two dose regimens of pralidoxime in the management of organophosphate poisoning. Asia Pac J Med Toxicol 2:121–125Google Scholar
- 37.Baloch GH, Khan AH, Madhudas C, Devrajani BR, Shah SZ, Das T, Shah SF (2018) Outcome of acute organophosphorus poisoning at Liaquat University Hospital Hyderabad. World Appl Sci J 13:266–268Google Scholar
- 41.Cherian AM, Peter JV, Samuel J, Jaydevan R, Peter S, Joel S, Jeyasselan L, Thomas K (1997) Effectiveness of P2AM (PAM -pralidoxime) in the treatment of organophosphorus poisoning. A randomised, double blind placebo controlled trial. J Assoc Physicians India 45:22–24Google Scholar
- 44.Ramesh Unnikrishnan AS (2012) Clinical outcomes of patients admitted with organophosphorus poisoning in a tertiary hospital in Udupi district Indian. J Respir Care 1:59–65Google Scholar
- 45.Anju N, Nalini P (2010) Comparison of efficacy and safety of atropine sulphate and glycopyrrolate in the treatment of organophosphorus poisoning at St. Martha’s Hospital, Bangalore. Indian J Pharm Pract 3:43–46Google Scholar
- 47.Chugh SN, Aggarwal N, Dabla S, Chhabra B (2005) Comparative evaluation of “atropine alone” and “atropine with pralidoxime (PAM)” in the management of organophosphorus poisoning. J Indian Acad Clin Med 6:33–37Google Scholar